CliffBio
small molecule

AZILSARTAN MEDOXOMIL

AZILSARTAN KAMEDOXOMIL

Loss of exclusivityDecember 2026FDA regulatory exclusivity expiry
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameAZILSARTAN MEDOXOMIL
Active ingredientAZILSARTAN KAMEDOXOMIL
StrengthEQ 40MG MEDOXOMIL
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2022
Marketing statusRX

Regulatory exclusivity

CodeExpires
PCDecember 2026

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

AZILSARTAN MEDOXOMIL patent cliff — loss of exclusivity December 2026 | CliffBio